← Back to Search

Behavioural Intervention

Chiropractic Care for Multiple Sclerosis

N/A
Recruiting
Led By William R Reed, DC, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 to 55 years
No known cardiovascular, pulmonary, or metabolic disease
Must not have
Any past spinal surgery or recent history of bone fractures
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4 (after 8th treatment)

Summary

This trial will test the effects of spinal manipulation on pro- and anti-inflammatory markers in people with MS.

Who is the study for?
This trial is for adults aged 18-55 with a recent diagnosis of relapsing-remitting Multiple Sclerosis (MS), who are stable on FDA-approved MS medications, and have not had an MS flare-up in the past month. They should be new to chiropractic care, free from major diseases or conditions that affect the heart, lungs, or metabolism, and must not have had spinal surgery or bone fractures recently.
What is being tested?
The study tests if chiropractic care can influence immune markers in people with MS. Participants will receive either real spinal manipulation treatments or sham (fake) ones over four weeks to see how their cytokine levels change immediately after treatment and cumulatively.
What are the potential side effects?
While specific side effects aren't listed for this trial, typical risks of spinal manipulation may include temporary discomfort at the site of adjustment, headaches, fatigue, and rarely more serious complications like herniated disks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 55 years old.
Select...
I do not have any known heart, lung, or metabolic diseases.
Select...
I can safely undergo spinal manipulation.
Select...
My disability score is below 4, indicating I can walk without aid or rest for 500m.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had spinal surgery or recent bone fractures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4 (after 8th treatment)
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 (after 8th treatment) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Serum inflammatory cytokine levels
Secondary study objectives
Cognitive Processing Speed
Fatigue Severity Scale
Hospital Anxiety Depression Scale
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Spinal ManipulationExperimental Treatment1 Intervention
The spinal manipulation (SM) group will receive manually delivered SM limited to the thoracic spine.
Group II: Sham Spinal ManipulationPlacebo Group1 Intervention
Sham-spinal manipulation will be delivered by setting the expansion control knob on an Activator II (Activator Methods®) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician. At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,645 Previous Clinical Trials
2,342,828 Total Patients Enrolled
38 Trials studying Multiple Sclerosis
45,339 Patients Enrolled for Multiple Sclerosis
William R Reed, DC, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham

Media Library

Spinal Manipulation (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04972929 — N/A
Multiple Sclerosis Research Study Groups: Spinal Manipulation, Sham Spinal Manipulation
Multiple Sclerosis Clinical Trial 2023: Spinal Manipulation Highlights & Side Effects. Trial Name: NCT04972929 — N/A
Spinal Manipulation (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04972929 — N/A
~1 spots leftby Dec 2024